Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 M3PHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;qdYQ3UUN3ME2wMlAxODJ6NzFOwG0> MlX2V2FPT0WU
LC-2-ad Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMECwN|E4KM7:TR?= M3LQfnNCVkeHUh?=
RL95-2 M{i3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWzUZlKSzVyPUCuNFAxPjZ6IN88US=> Mln5V2FPT0WU
MZ1-PC MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHOTWM2OD1yLkCwNFczQSEQvF2= Mon3V2FPT0WU
TE-8 M3\lfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMECxNVch|ryP NUmxfJVlW0GQR1XS
SW954 Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\VXm1KSzVyPUCuNFAyOTlizszN M4rpPXNCVkeHUh?=
TE-11 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3GyN2lEPTB;MD6wNFEzOyEQvF2= MX;TRW5ITVJ?
PSN1 M3LZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LFSGlEPTB;MD6wNFE{KM7:TR?= MnXGV2FPT0WU
MOLT-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\uTWM2OD1yLkCwNVQ6KM7:TR?= NWrMO|BxW0GQR1XS
697 NHS2O3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHSTWM2OD1yLkCwNVUh|ryP NV7Eb5MyW0GQR1XS
ETK-1 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7lTWM2OD1yLkCwNVUzKM7:TR?= NH3L[XpUSU6JRWK=
TE-10 NEXzPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfmd29LUUN3ME2wMlAxOTV2IN88US=> NYXne2txW0GQR1XS
HUTU-80 NI\lZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXTWGIyUUN3ME2wMlAxOTZ6IN88US=> Ml\4V2FPT0WU
NTERA-S-cl-D1 NV7hSFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13LOGlEPTB;MD6wNFIxQSEQvF2= M2W4[XNCVkeHUh?=
MFH-ino MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHITWM2OD1yLkCwNlY5KM7:TR?= NWnpVVJiW0GQR1XS
IA-LM NFS3eJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMECyPEDPxE1? MnvSV2FPT0WU
MC116 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTnXYJKSzVyPUCuNFAzQDlizszN MoPvV2FPT0WU
RKO MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMECyPVgh|ryP MoLlV2FPT0WU
MRK-nu-1 M4DIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3TeW0yUUN3ME2wMlAxOjl7IN88US=> Mkn5V2FPT0WU
VA-ES-BJ M3PPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDmTmNyUUN3ME2wMlAxOyEQvF2= M3HhbnNCVkeHUh?=
KALS-1 NXqweJlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfJO4JWUUN3ME2wMlAxOzB6IN88US=> NV;Yb5k5W0GQR1XS
BB30-HNC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXkXFRKSzVyPUCuNFA{OTRizszN NYTad5BQW0GQR1XS
ACN M1TGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r3[GlEPTB;MD6wNFMyPiEQvF2= NXTiZXJnW0GQR1XS
TE-9 M4S5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr0R|dHUUN3ME2wMlAxOzJ4IN88US=> NGr1T3NUSU6JRWK=
SIG-M5 NYrLToZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz3O4lKSzVyPUCuNFA{OjdizszN MW\TRW5ITVJ?
no-10 NH;ON3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6wSmdXUUN3ME2wMlAxOzZ{IN88US=> Mn\6V2FPT0WU
EW-1 NXzpeZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrGbpNKSzVyPUCuNFA{PzFizszN Mn3FV2FPT0WU
SK-LMS-1 M1vHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvLfGhKSzVyPUCuNFA1ODFizszN NFvQO3dUSU6JRWK=
GT3TKB MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH1cJpDUUN3ME2wMlAxPDN2IN88US=> MVfTRW5ITVJ?
ES4 M3vvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq0TWM2OD1yLkCwOFQ6KM7:TR?= NEHESlFUSU6JRWK=
IMR-5 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEC0OUDPxE1? NUe2d5NKW0GQR1XS
NCI-H1648 NHHSW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;lUlJ7UUN3ME2wMlAxPDZ7IN88US=> NVK2fm9IW0GQR1XS
MV-4-11 Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMEC0O|Uh|ryP MnPqV2FPT0WU
SK-UT-1 NFXqVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfJUItiUUN3ME2wMlAxPDhizszN MYDTRW5ITVJ?
NB13 NHSwcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTmc3dKSzVyPUCuNFA1QTFizszN MUfTRW5ITVJ?
DJM-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDQXZFKSzVyPUCuNFA2OyEQvF2= M{LWbHNCVkeHUh?=
ES8 NHL2c3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HBZmlEPTB;MD6wNFU{QCEQvF2= NVLNXG5LW0GQR1XS
TE-6 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTq[pFiUUN3ME2wMlAxPTdizszN MmjQV2FPT0WU
KS-1 NWDqbVdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMEC1PFIh|ryP MnzxV2FPT0WU
TE-1 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrY[2hnUUN3ME2wMlAxPjB4IN88US=> NWfPSWFuW0GQR1XS
ATN-1 NIfDXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fQfGlEPTB;MD6wNFYxQSEQvF2= M1ftdHNCVkeHUh?=
A4-Fuk NF7qfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEC2NVEh|ryP NEfEW2tUSU6JRWK=
ALL-PO NFzBWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjqW2lKSzVyPUCuNFA3OyEQvF2= NUfYXolNW0GQR1XS
BE-13 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LBTWlEPTB;MD6wNFY{PiEQvF2= NVzIfXB5W0GQR1XS
KM12 MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vOZWlEPTB;MD6wNFY{PyEQvF2= MUnTRW5ITVJ?
NOS-1 NGXHNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T2XWlEPTB;MD6wNFY2KM7:TR?= NIXyTZNUSU6JRWK=
SW962 NVPnW4U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLvPIVDUUN3ME2wMlAxPjZ{IN88US=> M4PDUHNCVkeHUh?=
OCUB-M MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf2XmRlUUN3ME2wMlAxPjZ{IN88US=> M4DHTnNCVkeHUh?=
NCI-H510A NHXDTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK1PHVKSzVyPUCuNFA3PjVizszN NXewcodZW0GQR1XS
EW-16 NEjQdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvZ[FdiUUN3ME2wMlAxPjl2IN88US=> M2DDRXNCVkeHUh?=
KGN NVnpSoFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O2UWlEPTB;MD6wNFcyOiEQvF2= NVzJNHZXW0GQR1XS
LS-411N MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPX[pNKSzVyPUCuNFA4OTdizszN MVHTRW5ITVJ?
Becker NHXVdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTVelRKSzVyPUCuNFA4OiEQvF2= Mmr5V2FPT0WU
HC-1 MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfWZlNmUUN3ME2wMlAxPzJzIN88US=> NELuRmJUSU6JRWK=
CESS NXrwd3FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTLTWM2OD1yLkCwO|M4KM7:TR?= MV;TRW5ITVJ?
KURAMOCHI M4f0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTNPGM2UUN3ME2wMlAxPzR6IN88US=> MW\TRW5ITVJ?
TGBC24TKB M4rpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqzXodKSzVyPUCuNFA4PTJizszN MmfMV2FPT0WU
SW982 NGf5fVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKwWJFKSzVyPUCuNFA4PjZizszN NGDibXZUSU6JRWK=
HCE-4 NVnjUHV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj3SJpKSzVyPUCuNFA4PjdizszN M33IfHNCVkeHUh?=
LOUCY NEPLcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jvVmlEPTB;MD6wNFc4PSEQvF2= NGPaWplUSU6JRWK=
8-MG-BA M1Lle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEC3PVYh|ryP NF;aeo1USU6JRWK=
HT-144 NYjQV4N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTvdm1PUUN3ME2wMlAxQCEQvF2= MVjTRW5ITVJ?
LXF-289 M4\3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEC4NVgh|ryP MkHWV2FPT0WU
RS4-11 NHywOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV65eFdpUUN3ME2wMlAxQDN4IN88US=> NUnpXmNtW0GQR1XS
DEL NHGzZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDZbZRLUUN3ME2wMlAxQDR3IN88US=> NUXJfJBIW0GQR1XS
OCI-AML2 NH7Z[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPlV|JyUUN3ME2wMlAxQDV{IN88US=> MUPTRW5ITVJ?
CCRF-CEM MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTkTWM2OD1yLkCwPFcyKM7:TR?= NILrfFlUSU6JRWK=
A388 M1rXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHvR3RKSzVyPUCuNFA5PzRizszN M2DDeXNCVkeHUh?=
KNS-42 M{Xsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fNbGlEPTB;MD6wNFg6OSEQvF2= NHTuPXNUSU6JRWK=
OVCAR-4 NHjqRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Zc3pKSzVyPUCuNFA6ODRizszN MXHTRW5ITVJ?
NCI-H1355 M3u2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\IUYhWUUN3ME2wMlAxQTF2IN88US=> MlPFV2FPT0WU
BL-70 NEnLU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuzb4NKSzVyPUCuNFA6OyEQvF2= MmL2V2FPT0WU
BL-41 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMEC5N|Qh|ryP NInYfW1USU6JRWK=
A101D NIPHdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvUOHJKSzVyPUCuNFA6PiEQvF2= NHTDbJhUSU6JRWK=
HL-60 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTMOFZOUUN3ME2wMlAxQTZ4IN88US=> M13hWnNCVkeHUh?=
COR-L279 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[z[4dKSzVyPUCuNFA6QTlizszN MYTTRW5ITVJ?
NCI-SNU-16 M2G3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIewSVJKSzVyPUCuNFExODhizszN NGrwPINUSU6JRWK=
Calu-6 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzUTWM2OD1yLkCxNFEzKM7:TR?= MlTJV2FPT0WU
SR Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOyTWM2OD1yLkCxNFI3KM7:TR?= NIWwPVJUSU6JRWK=
QIMR-WIL MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEGwN|Mh|ryP MnXFV2FPT0WU
LB647-SCLC NIfjRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEGwOVEh|ryP NYXjfZlyW0GQR1XS
RPMI-8226 NVPQXYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[5empKSzVyPUCuNFEyODJizszN NHPyWpVUSU6JRWK=
SK-PN-DW NVrreItWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEGxNVIh|ryP NFznbnVUSU6JRWK=
SF268 NGTiTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi3Vo1tUUN3ME2wMlAyOTVzIN88US=> NHfseHBUSU6JRWK=
HD-MY-Z MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLRepdKSzVyPUCuNFEyPjNizszN MmG0V2FPT0WU
DOHH-2 NYrje4NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEGyNFMh|ryP MoX5V2FPT0WU
SCC-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v5cWlEPTB;MD6wNVIxPCEQvF2= NFvPXnNUSU6JRWK=
ST486 MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMEGyNFQh|ryP MnjoV2FPT0WU
NALM-6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTGTWM2OD1yLkCxNlE1KM7:TR?= NVLiZodXW0GQR1XS
NCI-H1436 NF\QXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6xTWM2OD1yLkCxNlMyKM7:TR?= M1LBc3NCVkeHUh?=
KE-37 NWj0NlNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;VemlEPTB;MD6wNVI{PCEQvF2= M4PmWXNCVkeHUh?=
RPMI-8402 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHEdodQUUN3ME2wMlAyOjV4IN88US=> MVnTRW5ITVJ?
RXF393 NVPJS|ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILKbYFKSzVyPUCuNFEzPTdizszN M1\YRnNCVkeHUh?=
KARPAS-45 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n5PWlEPTB;MD6wNVI4KM7:TR?= MkXJV2FPT0WU
HOP-62 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rTOWlEPTB;MD6wNVI4PiEQvF2= MWfTRW5ITVJ?
ES1 M4Xnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13GWmlEPTB;MD6wNVI5QCEQvF2= MlPqV2FPT0WU
L-363 M3viZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TFRWlEPTB;MD6wNVM2OSEQvF2= M{C2NnNCVkeHUh?=
GI-1 NHe3c5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\BTWM2OD1yLkCxN|c{KM7:TR?= NEnFfpdUSU6JRWK=
CTV-1 NF;3UZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnJ[5JsUUN3ME2wMlAyPDd6IN88US=> M33udXNCVkeHUh?=
TE-5 M2i2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEG0PVYh|ryP NVTERVI4W0GQR1XS
SNU-C2B MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnMTWM2OD1yLkCxOFk3KM7:TR?= MlzTV2FPT0WU
K-562 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnXUJJPUUN3ME2wMlAyPTF4IN88US=> M{\YVXNCVkeHUh?=
SNB75 NILtc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMEG1OEDPxE1? Ml3SV2FPT0WU
MOLT-13 NFr6U5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13IXWlEPTB;MD6wNVY{PyEQvF2= NF32e4xUSU6JRWK=
LS-123 NYXUeHdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEG2OlQh|ryP NGH5S4JUSU6JRWK=
NCI-SNU-5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnwOnJpUUN3ME2wMlAyPzBzIN88US=> M17aPHNCVkeHUh?=
Daudi M3n5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzzTWM2OD1yLkCxO|A5KM7:TR?= MmrRV2FPT0WU
A253 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e0bWlEPTB;MD6wNVc{QCEQvF2= MYjTRW5ITVJ?
TGBC1TKB M2DMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LCZWlEPTB;MD6wNVc2OiEQvF2= MV;TRW5ITVJ?
SJSA-1 M374eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j6cWlEPTB;MD6wNVc3PyEQvF2= MV3TRW5ITVJ?
NCCIT NXvtVGF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqzTWM2OD1yLkCxO|Y6KM7:TR?= M{jofnNCVkeHUh?=
NCI-H69 NHnmV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TtOGlEPTB;MD6wNVc4QCEQvF2= M4rtcXNCVkeHUh?=
SH-4 NWHxWVVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17RcWlEPTB;MD6wNVg6PSEQvF2= MYDTRW5ITVJ?
HCC1187 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEG5NlQh|ryP MVzTRW5ITVJ?
HCC1599 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm1[ng3UUN3ME2wMlAzODJizszN MVzTRW5ITVJ?
ONS-76 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvD[VMxUUN3ME2wMlAzODN4IN88US=> Mme2V2FPT0WU
KU812 M4Pnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hj[mlEPTB;MD6wNlA{QSEQvF2= NF3lPHBUSU6JRWK=
ML-2 NHzlelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEKwOFch|ryP M1nWOnNCVkeHUh?=
HCE-T NFjtWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMEKwPVIh|ryP NWjXdXlYW0GQR1XS
NCI-H446 M2HxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfV[GxzUUN3ME2wMlAzOTF{IN88US=> NUjW[oRJW0GQR1XS
RPMI-6666 NFLRfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTrTFRVUUN3ME2wMlAzOTR7IN88US=> MoPSV2FPT0WU
MOLT-16 NYTTRZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEKxOVMh|ryP Mk\qV2FPT0WU
JiyoyeP-2003 NHvBV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;ncFZ5UUN3ME2wMlAzOTd4IN88US=> NEHkVHhUSU6JRWK=
MHH-PREB-1 NH\rTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKzTFRKSzVyPUCuNFIyQTFizszN NVLSdItpW0GQR1XS
MC-CAR Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;tbY5KSzVyPUCuNFI{OjZizszN NFXlTZVUSU6JRWK=
BC-3 MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEKzOFQh|ryP M3TXU3NCVkeHUh?=
KINGS-1 NHOxOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HhU2lEPTB;MD6wNlM2PSEQvF2= MofVV2FPT0WU
PF-382 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S4O2lEPTB;MD6wNlM4QCEQvF2= MW\TRW5ITVJ?
J-RT3-T3-5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zheGlEPTB;MD6wNlM5OyEQvF2= MXTTRW5ITVJ?
SF539 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF71[oxKSzVyPUCuNFI1ODFizszN NWTSbHdyW0GQR1XS
LB831-BLC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV2wfXpvUUN3ME2wMlAzPDh3IN88US=> MYfTRW5ITVJ?
DMS-114 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELISpdKSzVyPUCuNFI2ODJizszN M1jOUXNCVkeHUh?=
LB1047-RCC MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfTbHpYUUN3ME2wMlAzPTFizszN NFHxeFFUSU6JRWK=
LB771-HNC NUH1RWt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HTfWlEPTB;MD6wNlU{PCEQvF2= NYr6RnlkW0GQR1XS
BB65-RCC MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMEK1N|Qh|ryP MoLrV2FPT0WU
BV-173 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mwR2lEPTB;MD6wNlU2PCEQvF2= NFjCTVNUSU6JRWK=
ARH-77 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEK2NFEh|ryP NHL4PFJUSU6JRWK=
IST-MEL1 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMEK2NlMh|ryP MVjTRW5ITVJ?
NB1 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zKZWlEPTB;MD6wNlY5PyEQvF2= Mk\pV2FPT0WU
EoL-1-cell MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojETWM2OD1yLkCyOlg5KM7:TR?= NEfUUXRUSU6JRWK=
KY821 NY[3[Y1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTkOmt1UUN3ME2wMlAzPjl5IN88US=> M1vIVHNCVkeHUh?=
CMK MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEK3N|Qh|ryP M2O0W3NCVkeHUh?=
NCI-H2126 M3XTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfNWVdzUUN3ME2wMlAzPzZ6IN88US=> MUDTRW5ITVJ?
NCI-H526 M3nnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nybmlEPTB;MD6wNlg6OSEQvF2= NGTsVGxUSU6JRWK=
COLO-684 NX:wb4Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\ZSIJHUUN3ME2wMlAzQTB6IN88US=> NHqxXVBUSU6JRWK=
NCI-H747 NEXOcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HMT2lEPTB;MD6wNlk{OyEQvF2= NIr3UolUSU6JRWK=
JAR NIO5dWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMEK5OFYh|ryP MVvTRW5ITVJ?
MEG-01 M1W2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEK5O|gh|ryP MlfRV2FPT0WU
MONO-MAC-6 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXabVNKSzVyPUCuNFMxOjNizszN NUXLZ|R[W0GQR1XS
IST-SL1 M3nBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHiTWM2OD1yLkCzNFQzKM7:TR?= MXnTRW5ITVJ?
CPC-N M{j3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jqc2lEPTB;MD6wN|A4QSEQvF2= MWTTRW5ITVJ?
NCI-H1963 NE\VToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{juS2lEPTB;MD6wN|E{OSEQvF2= MUnTRW5ITVJ?
K052 NWXE[mVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHBV29KSzVyPUCuNFMzPDdizszN MkTGV2FPT0WU
KM-H2 NXToemNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PPRmlEPTB;MD6wN|MxPyEQvF2= NVTMOJJTW0GQR1XS
TE-12 MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEOzNFkh|ryP MkDXV2FPT0WU
TK10 NH\D[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjkS3ZzUUN3ME2wMlA{OzV4IN88US=> MonwV2FPT0WU
NMC-G1 NVvlTlN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TQZ2lEPTB;MD6wN|Q2OiEQvF2= MWLTRW5ITVJ?
no-11 M4j5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\qTWM2OD1yLkCzOFc5KM7:TR?= MnezV2FPT0WU
NCI-H524 NFT3XIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrFTWM2OD1yLkCzOVI6KM7:TR?= MX7TRW5ITVJ?
MHH-CALL-2 NV76UoJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz4TWM2OD1yLkCzOVYzKM7:TR?= NV\v[FR1W0GQR1XS
GB-1 NEXqeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMEO2JO69VQ>? MXjTRW5ITVJ?
OPM-2 MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMEO2O|Mh|ryP NIS1W|ZUSU6JRWK=
RH-1 M1[xSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMEO4NVkh|ryP NEHWWYFUSU6JRWK=
NCI-H64 NFzINnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzaTWM2OD1yLkCzPFU4KM7:TR?= NIDxbFRUSU6JRWK=
EVSA-T NEOxW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX2bWVKSzVyPUCuNFM6OjNizszN NWDC[5ZzW0GQR1XS
KARPAS-299 M3rIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEO5PEDPxE1? MlK4V2FPT0WU
MZ7-mel NUDFd|c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknRTWM2OD1yLkC0NFQh|ryP MU\TRW5ITVJ?
LB373-MEL-D MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nTcWlEPTB;MD6wOFExPSEQvF2= MVnTRW5ITVJ?
HEL NHzlZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fsT2lEPTB;MD6wOFE1KM7:TR?= MWfTRW5ITVJ?
SW872 Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j2TWlEPTB;MD6wOFIyKM7:TR?= Moi0V2FPT0WU
DU-4475 NIr5T|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMESyOFQh|ryP NWnwWopOW0GQR1XS
IST-SL2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fh[WlEPTB;MD6wOFI4PSEQvF2= MUfTRW5ITVJ?
NCI-H82 NWfFfGdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofCTWM2OD1yLkC0N|A4KM7:TR?= M4S5T3NCVkeHUh?=
LC4-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;yTWM2OD1yLkC0N|UyKM7:TR?= M{XOfHNCVkeHUh?=
HDLM-2 NVvxZlJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO1TWM2OD1yLkC0N|kzKM7:TR?= M{jYTHNCVkeHUh?=
MMAC-SF NFvi[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7Od3pKSzVyPUCuNFQ2OzRizszN Ml3DV2FPT0WU
L-540 NUPPWI4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlezTWM2OD1yLkC0OlM6KM7:TR?= MkPLV2FPT0WU
MZ2-MEL MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPaTWM2OD1yLkC0O|QzKM7:TR?= NYjrWopZW0GQR1XS
LU-134-A MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17o[2lEPTB;MD6wOFc4OyEQvF2= NXXSOlk{W0GQR1XS
UACC-257 NX\EXJhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLRXJJKSzVyPUCuNFQ5PDlizszN MkjIV2FPT0WU
NCI-H1581 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMES5OVMh|ryP NEe4XZRUSU6JRWK=
NB17 M1jT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\wTWM2OD1yLkC0PVc6KM7:TR?= MULTRW5ITVJ?
SBC-1 NH63bWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfjXoNKSzVyPUCuNFUxPDJizszN NUXBZ4J5W0GQR1XS
TALL-1 NHfG[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTSTWM2OD1yLkC1NFQ2KM7:TR?= NVrQ[lJyW0GQR1XS
NCI-H1304 M1XkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEWyNFgh|ryP MoDlV2FPT0WU
NEC8 NH\mW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrFTWM2OD1yLkC1Nlg3KM7:TR?= MUTTRW5ITVJ?
CAL-148 NUPRbo5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHCV3pFUUN3ME2wMlA2PDN7IN88US=> NF7mUppUSU6JRWK=
CGTH-W-1 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTPPWlKSzVyPUCuNFU1PDlizszN NYO5XJFrW0GQR1XS
NCI-H889 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEW1PVIh|ryP Mm\QV2FPT0WU
GR-ST MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMEW2NlEh|ryP MXLTRW5ITVJ?
KARPAS-422 M4fMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG2OIRQUUN3ME2wMlA2PjVizszN M{PTSXNCVkeHUh?=
RPMI-8866 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULBbohtUUN3ME2wMlA2PzF{IN88US=> M4W5XHNCVkeHUh?=
SCLC-21H NWP2OlJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T5S2lEPTB;MD6wOVg5PCEQvF2= NHW5[lRUSU6JRWK=
COR-L88 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnObGd2UUN3ME2wMlA2QTJ5IN88US=> NHrORpdUSU6JRWK=
LU-139 M3TuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHkU3I1UUN3ME2wMlA2QTh4IN88US=> NGTNfm1USU6JRWK=
SF126 NXzoW5JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlKyTWM2OD1yLkC2NVM{KM7:TR?= M2e5R3NCVkeHUh?=
NCI-H1882 NF;uVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfPd2xjUUN3ME2wMlA3PDJ2IN88US=> MnWwV2FPT0WU
EW-24 NWHwUW1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\abnNpUUN3ME2wMlA3PDh|IN88US=> MlfPV2FPT0WU
CP67-MEL M3H0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwME[4NUDPxE1? MYLTRW5ITVJ?
DG-75 NULnb4hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljKTWM2OD1yLkC2PFk6KM7:TR?= Mo\oV2FPT0WU
LOXIMVI M2LYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjnWoJKSzVyPUCuNFcxOjhizszN MXHTRW5ITVJ?
HH MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi0cYlWUUN3ME2wMlA4OTV5IN88US=> NFjU[FFUSU6JRWK=
K5 NUjxelhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f2WWlEPTB;MD6wO|IzPiEQvF2= NI[3XG9USU6JRWK=
EC-GI-10 M4PRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\MTJhKSzVyPUCuNFczPTdizszN NXXzRXRrW0GQR1XS
SK-N-DZ M3PmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEezNFch|ryP NYjTZo1XW0GQR1XS
A3-KAW NF;MOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jaTGlEPTB;MD6wO|M2OSEQvF2= NHzNUo9USU6JRWK=
MLMA NGXHSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zSO2lEPTB;MD6wO|Q3PSEQvF2= MnflV2FPT0WU
LB996-RCC NF72R3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;LTWM2OD1yLkC3O|A4KM7:TR?= NHLSbZpUSU6JRWK=
OS-RC-2 NX7tRZluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrzTWM2OD1yLkC3O|Q5KM7:TR?= M2jKenNCVkeHUh?=
CTB-1 M4fPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMEe4NUDPxE1? NFSycXZUSU6JRWK=
IST-MES1 NGn1OZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fi[WlEPTB;MD6wO|kyOiEQvF2= M4\tN3NCVkeHUh?=
LS-1034 NFnURlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEiwN|Uh|ryP NITjd2VUSU6JRWK=
HT NU\Tco1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3iZmdKSzVyPUCuNFgxQDZizszN NYjTRVliW0GQR1XS
NCI-H2141 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm0PGdMUUN3ME2wMlA5OSEQvF2= MVHTRW5ITVJ?
LB2518-MEL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDUfWYzUUN3ME2wMlA5OTRzIN88US=> NYHIT3pyW0GQR1XS
GI-ME-N NGnwZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrJOVJKSzVyPUCuNFg1PTJizszN NGL3PGxUSU6JRWK=
TGW MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;pVmJ3UUN3ME2wMlA5PjB5IN88US=> M2rzO3NCVkeHUh?=
SK-NEP-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPCTWM2OD1yLkC4OlQyKM7:TR?= NXHlepBjW0GQR1XS
NOMO-1 NVK5SZdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfidGlbUUN3ME2wMlA6Ojd3IN88US=> M3zRV3NCVkeHUh?=
ES6 NWLYUZlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDyTWM2OD1yLkC5OVg6KM7:TR?= NUWyS3N6W0GQR1XS
NCI-H209 M2jtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j2SmlEPTB;MD6wPVc5PiEQvF2= NGTZXWhUSU6JRWK=
GAK NVTWPFFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;RWXVwUUN3ME2wMlExOTZizszN NUjJ[5NsW0GQR1XS
BC-1 NV3CSpFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXXdYlzUUN3ME2wMlExOzZzIN88US=> MmHNV2FPT0WU
KLE NVHNRYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT6cYM{UUN3ME2wMlExPDR|IN88US=> MmPhV2FPT0WU
EW-3 M4n4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zIcGlEPTB;MD6xNFk5KM7:TR?= MYHTRW5ITVJ?
NKM-1 M2jGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMUGxJO69VQ>? MVfTRW5ITVJ?
D-336MG M3HXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL0TWM2OD1yLkGxNlQ1KM7:TR?= MoP6V2FPT0WU
NB69 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\nfXdmUUN3ME2wMlEyOzBzIN88US=> MVnTRW5ITVJ?
D-263MG MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW4cGRKSzVyPUCuNVE4OTJizszN NWDMcmZ5W0GQR1XS
KP-N-YS NFrUT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTUTWM2OD1yLkGyNlkyKM7:TR?= MnXLV2FPT0WU
NCI-H1155 M2K1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vWOGlEPTB;MD6xNlU2QCEQvF2= MWPTRW5ITVJ?
BOKU Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHw[VdKSzVyPUCuNVI2PzlizszN NVvKRWJsW0GQR1XS
LAMA-84 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMUK5PUDPxE1? MX\TRW5ITVJ?
Raji M3vrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\mTWM2OD1yLkGzNVE4KM7:TR?= NX\TSY5WW0GQR1XS
LU-65 NHuzdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnBRXlKSzVyPUCuNVM{ODdizszN MV3TRW5ITVJ?
NCI-H187 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMUO5NlQh|ryP MYjTRW5ITVJ?
GCIY MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzBWJJKSzVyPUCuNVQ6ODFizszN MmDHV2FPT0WU
NCI-H2107 NUXOcZZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMUWwPEDPxE1? NWTJfmViW0GQR1XS
NCI-H1522 NXzkVlBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn63TWM2OD1yLkG1NlY3KM7:TR?= M4jvTnNCVkeHUh?=
NB6 NXy4b3d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMUW2NlMh|ryP MX\TRW5ITVJ?
EM-2 NWnJVmtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof2TWM2OD1yLkG1O|A3KM7:TR?= NWe3XnRoW0GQR1XS
HCC2218 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml22TWM2OD1yLkG1PVgh|ryP Mlv2V2FPT0WU
NCI-H748 Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMU[zO|Yh|ryP NHfxRXpUSU6JRWK=
MS-1 NIXBZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjmTWM2OD1yLkG2OVM4KM7:TR?= NWXMeZhZW0GQR1XS
NB5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X2VGlEPTB;MD6xOlU6PyEQvF2= MmjkV2FPT0WU
OMC-1 NUPWZpg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7tVVlKSzVyPUCuNVY3QDhizszN NF64R2lUSU6JRWK=
NCI-H345 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rJcmlEPTB;MD6xOlkzQCEQvF2= MmfhV2FPT0WU
L-428 NF:yeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP6ZpJKSzVyPUCuNVY6PDVizszN NFzQO25USU6JRWK=
SCH MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXhTWM2OD1yLkG4Olg2KM7:TR?= NVy0UpZGW0GQR1XS
NCI-H1417 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\0TWM2OD1yLkG5NlI4KM7:TR?= MkmxV2FPT0WU
COLO-320-HSR MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\HPWlEPTB;MD6xPVU{OiEQvF2= M4PWVnNCVkeHUh?=
BT-474 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLITWM2OD1yLkKwPFkzKM7:TR?= MYjTRW5ITVJ?
GDM-1 M1XFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\KTGlEPTB;MD6yNVk4OSEQvF2= NHfqWJJUSU6JRWK=
NCI-H2196 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnWTWM2OD1yLkKyNlM2KM7:TR?= NXv0dm4{W0GQR1XS
KP-N-RT-BM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMkKzOFkh|ryP Moi3V2FPT0WU
KNS-81-FD NIPWeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLGNId[UUN3ME2wMlIzQTV6IN88US=> M4LjO3NCVkeHUh?=
COLO-668 M2rrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMkO2O|Uh|ryP NHjYXXNUSU6JRWK=
C2BBe1 NITpWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMk[3OFch|ryP M3fpfHNCVkeHUh?=
Ramos-2G6-4C10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMk[5OVQh|ryP MmfTV2FPT0WU
CAS-1 M1zGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHPTWM2OD1yLkK3NFk3KM7:TR?= M2fFbHNCVkeHUh?=
GOTO NGLueW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLoWIFKSzVyPUCuNlc5QTRizszN MoH4V2FPT0WU
LP-1 NIHGdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PoOWlEPTB;MD6yPFA2PyEQvF2= M3jVOXNCVkeHUh?=
NCI-SNU-1 M2W3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm5TWM2OD1yLkK5OFIzKM7:TR?= Mn30V2FPT0WU
EB-3 NHWybVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7QUo9KSzVyPUCuNlk6PzlizszN MWfTRW5ITVJ?
MHH-NB-11 NIXHbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHYTWM2OD1yLkOwOFAzKM7:TR?= NIn5O5pUSU6JRWK=
SK-N-FI MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnKTWM2OD1yLkOxOlkzKM7:TR?= MmnzV2FPT0WU
HCC2157 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrkRWhbUUN3ME2wMlM{QTF|IN88US=> Mn3BV2FPT0WU
SIMA M2DoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz3dWJKSzVyPUCuN|Q2QDFizszN M3vIZXNCVkeHUh?=
MDA-MB-134-VI M3\ESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHsZodKSzVyPUCuN|Y6OjhizszN M3;sVXNCVkeHUh?=
NCI-H1694 NGm2WpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwM{eg{txO NF64PW5USU6JRWK=
EHEB M3\pNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorVTWM2OD1yLkO5NFg2KM7:TR?= MoO1V2FPT0WU
U-266 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPYZW5KSzVyPUCuN|k5PDZizszN NVu5VpdkW0GQR1XS
LC-1F Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jPeWlEPTB;MD60N|c3PSEQvF2= MoLVV2FPT0WU
SHP-77 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\QTWM2OD1yLkS3PFU2KM7:TR?= M2Xwe3NCVkeHUh?=
LS-513 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP5TWM2OD1yLkS5N|A4KM7:TR?= MlizV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+5% Tween 80+ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID